Bridgewest Perth Pharma

Bridgewest Perth Pharma is a global pharmaceutical manufacturing company based in Perth, Australia, wholly owned by Bridgewest Group. It operates through two divisions: NovaCina (sterile injectable CDMO) and LumaCina (pharmaceutical marketing and supply). The company’s core business is the production of high-quality sterile injectable drugs, including oncology and high-potency APIs, using advanced blow-fill-seal and multi-format vial technologies. It continues to manufacture products previously made by Pfizer under a master services agreement, ensuring supply continuity for critical hospital medicines. The company is investing in expanded R&D and manufacturing capabilities to meet growing global demand for sterile injectables, with a strong regulatory track record and approvals from the FDA, TGA, and EMA